Introduction: Cervical cancer (CC) is a malignant neoplasm that originates from the abnormal proliferation of malignant cells in the tissues of the cervix, with human papillomavirus (HPV) being the main cause. In Brazil, screening enables the identification of precursor lesions and changes in the early and non-invasive stages of the disease, contributing to the reduction of cervical cancer-related morbidity and mortality. However, preventive measures still face challenges in reaching the minimum coverage of the target population, as areas with unfavorable socioeconomic conditions and greater barriers to healthcare continue to show higher incidence and mortality rates from cervical cancer. Objectives: To analyze the epidemiological profile of hospitalizations and deaths due to malignant neoplasm of the cervix in Brazil from 2020 to 2024. Methods: This is an epidemiological, descriptive, quantitative, and documentary study. Data were obtained from the Hospital Information System of the Brazilian Unified Health System (SIH-SUS), available on DATASUS. Cases of hospitalizations and deaths due to malignant neoplasm of the cervix in Brazil from 2020 to 2024 were analyzed, considering the variables: year of processing, region, federal unit, and age group. Results: A total of 130,388 hospitalizations were recorded during the analyzed period, with Southeastern(51,219; 39.3%) and Northeastern Brazil (33,908; 26.0%) being the most affected, while Central-Western and Northern Brazil showed lower rates, with 9,782 and 10,670 cases respectively. Among the states, São Paulo accounted for the highest number of hospitalizations (24,473), followed by Minas Gerais (12,238) and Paraná (11,283). A continuous national increase in hospitalizations was observed, with a 36.6% rise between 2020 (22,457 cases) and 2024 (30,676 cases), and all regions showed increases above 35%. The most affected age group was 40 to 49 years, with 36,810 hospitalizations (28.2%), followed by a progressive decline in older age groups. Regarding mortality, 13,794 deaths were recorded, with the highest concentrations in Southeastern (40.4%) and Northeastern Brazil (25.6%), and a stable trend in mortality rates between 2020 and 2024. Conclusion: According to the analysis, the data show a continuous increase in hospitalizations due to malignant neoplasm of the cervix in Brazil during the analyzed period, with emphasis on the Southeast and Northeast regions, indicating a greater burden of the disease and possible difficulties in accessing diagnosis. The prevalence among women aged 40 to 49 highlights the importance of more effective screening strategies, through expanded HPV vaccination coverage and the implementation of HPV-DNA molecular testing. Despite the stability in mortality rates, it is still necessary to strengthen existing public policies and develop new strategies aimed at the early detection of the disease.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
